Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 21 May 2009, Vol. 113, No. 21, pp. 5125-5133.
Prepublished online as a Blood First Edition Paper on March 18, 2009; DOI 10.1182/blood-2009-01-199950.

This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2009-01-199950v1
113/21/5125    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tran, D. Q.
Right arrow Articles by Shevach, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tran, D. Q.
Right arrow Articles by Shevach, E. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted January 16, 2009
Accepted March 12, 2009

Selective expression of latency associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures

Dat Q. Tran, John Andersson, Donna Hardwick, Lolita Bebris, Gabor G. Illei, and Ethan M. Shevach*

Laboratory of Immunology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States
Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health (NIH), Bethesda, MD, United States

* Corresponding author; email: eshevach{at}niaid.nih.gov.

While adoptive transfer of regulatory T cells (Foxp3+ Tregs) has proven to be efficacious in the prevention and treatment of autoimmune diseases and graft versus host disease in rodents, a major obstacle for the use of Treg immunotherapy in humans is the difficulty of obtaining a highly purified preparation following ex vivo expansion. We have identified latency-associated peptide (LAP) and IL-1 receptor type I and II (CD121a/CD121b) as unique cell surface markers that distinguish activated Tregs from activated FOXP3- and FOXP3+ non-Tregs. We demonstrate that it is feasible to sort expanded FOXP3+ Tregs from non-Tregs using magnetic bead cell separation techniques based on expression of these three markers. Post separation, the final product contains > 90% fully functional FOXP3+ Tregs. This novel protocol should facilitate the purification of Tregs for both cell-based therapies as well as for detailed studies of human Treg function in health and disease.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Q. Tran, J. Andersson, R. Wang, H. Ramsey, D. Unutmaz, and E. M. Shevach
GARP (LRRC32) is essential for the surface expression of latent TGF-{beta} on platelets and activated FOXP3+ regulatory T cells
PNAS, August 11, 2009; 106(32): 13445 - 13450.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020